Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GANX Stock Summary
Top 10 Correlated ETFs
In the News
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial.
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.
Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference
BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous System Disorders. The event is taking place at the Sheraton Boston in Boston, Massachusetts, between September 26-27, 2023.
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates
Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.
Gain Therapeutics to Present at the Jefferies Healthcare Conference
BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET.
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GANX Financial details
GANX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||0||0.01||0.01||0.02||0.01|
|Net income per share||-0.19||-0.37||-1.33||-1.37||-1.48|
|Operating cash flow per share||-0.13||-0.32||-1.21||-1.22||-1.24|
|Free cash flow per share||-0.13||-0.32||-1.22||-1.23||-1.25|
|Cash per share||0||0.05||2.79||3.63||1.69|
|Book value per share||0||-0.08||2.31||3.43||1.59|
|Tangible book value per share||0||-0.08||2.31||3.41||1.57|
|Share holders equity per share||0||-0.08||2.31||3.43||1.59|
|Interest debt per share||0||0.03||0.47||0.16||0.09|
|Price to sales ratio||3.18K||1.59K||1.04K||334.55||265.47|
|EV to sales||0||1.59K||824.08||120.77||222.38|
|Enterprise value over EBITDA||0||-32.25||-7.06||-1.45||-1.76|
|EV to operating cash flow||0||-35.07||-7.35||-1.61||-2.12|
|EV to free cash flow||0||-34.82||-7.3||-1.6||-2.1|
|Free cash flow yield||-0.01||-0.03||-0.11||-0.23||-0.4|
|Debt to equity||0||-0.45||0.2||0.05||0.07|
|Debt to assets||0||0.3||0.13||0.04||0.05|
|Net debt to EBITDA||0||0.05||1.85||2.56||0.34|
|Sales general and administrative to revenue||10.77||13.44||43.25||41.38||68.09|
|Research and developement to revenue||40.12||38.41||78.22||43.42||59.79|
|Intangibles to total assets||0||0||0||0.01||0.01|
|Capex to operating cash flow||0.01||0.01||0.01||0.01||0.01|
|Capex to revenue||-0.39||-0.33||-0.72||-0.57||-0.85|
|Capex to depreciation||-10.78||-5.34||-2.17||-6.08||-1.85|
|Stock based compensation to revenue||0||0||2.83||5.09||10.89|
|Return on tangible assets||0||-3.32||-0.37||-0.36||-0.74|
|Tangible asset value||0||-449.86K||6.2M||34.61M||18.67M|
|Net current asset value||0||-680.62K||5.59M||33.55M||15.87M|
|Days sales outstanding||0||396.94||841.25||251.28||270.61|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||0||0||-0.01||-0.01||-0.01|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||0||0.01||0||0||0|
|Net income per share||-0.38||-0.39||-0.43||-0.62||-0.37|
|Operating cash flow per share||-0.28||-0.33||-0.35||-0.41||-0.31|
|Free cash flow per share||-0.28||-0.33||-0.35||-0.41||-0.31|
|Cash per share||1.91||1.69||1.49||1.31||0.96|
|Book value per share||1.91||1.59||1.27||0.9||0.58|
|Tangible book value per share||1.89||1.57||1.25||0.88||0.56|
|Share holders equity per share||1.91||1.59||1.27||0.9||0.58|
|Interest debt per share||0.12||0.09||0.11||0.09||0.08|
|Price to sales ratio||0||265.47||1.04K||0||0|
|EV to sales||0||222.38||955.87||0||0|
|Enterprise value over EBITDA||-6.1||-7.17||-10.17||-6.58||-7.74|
|EV to operating cash flow||-8.86||-7.98||-12.51||-10.02||-9.69|
|EV to free cash flow||-8.7||-7.96||-12.47||-10.01||-9.69|
|Free cash flow yield||-0.09||-0.11||-0.07||-0.09||-0.1|
|Debt to equity||0.06||0.07||0.08||0.1||0.14|
|Debt to assets||0.04||0.05||0.06||0.06||0.07|
|Net debt to EBITDA||2.01||1.39||0.92||0.68||0.65|
|Sales general and administrative to revenue||0||16.33||45.19||0||0|
|Research and developement to revenue||0||16.23||50.58||0||0|
|Intangibles to total assets||0.01||0.01||0.01||0.01||0.01|
|Capex to operating cash flow||0.02||0||0||0||0|
|Capex to revenue||0||-0.07||-0.2||0||0|
|Capex to depreciation||-3.21||-0.52||-0.57||-0.18||-0.03|
|Stock based compensation to revenue||0||3.99||10.25||0||0|
|Return on tangible assets||-0.16||-0.2||-0.24||-0.43||-0.34|
|Tangible asset value||22.45M||18.67M||14.93M||10.89M||7.14M|
|Net current asset value||18.69M||15.87M||13.14M||10.14M||6.47M|
|Days sales outstanding||0||122.89||224.08||0||0|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||0||0||0||0||0|
GANX Frequently Asked Questions
What is Gain Therapeutics, Inc. stock symbol ?
Gain Therapeutics, Inc. is a US stock , located in Bethesda of Md and trading under the symbol GANX
Is Gain Therapeutics, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $7. The lowest prediction is $4 and the highest is $10
What is GANX stock prediction ?
What is Gain Therapeutics, Inc. stock quote today ?
Gain Therapeutics, Inc. stock price is $2.72 today.
Is Gain Therapeutics, Inc. stock public?
Yes, Gain Therapeutics, Inc. is a publicly traded company.